Welcome to our dedicated page for Lakeside Holding SEC filings (Ticker: LSH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lakeside Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lakeside Holding's regulatory disclosures and financial reporting.
Lakeside Holding (LSH) filed its annual report, highlighting a shift to a two-segment model and a challenging year. Total revenue was $17.8 million, down 2.9% year over year, as cross-border freight solutions fell 17.9% amid U.S. trade policy changes and softer demand. The company added a new line in December 2024, generating $2.8 million from pharmaceutical distribution.
Gross profit was $2.9 million (16.2% margin) versus $3.7 million (20.3%) last year, reflecting margin compression in freight (8.8% vs. 20.3%). Pharma posted a 56.1% gross margin, aided by supplier discounts as a new customer. Operating costs rose sharply—selling expenses increased with launch marketing, and G&A climbed 79.1%—driving a net loss of $5.25 million versus a $0.23 million loss a year ago. Interest expense increased 271.5%.
Liquidity at year-end included $5.0 million in cash, a current ratio of 1.06:1, positive working capital of $0.6 million, and $2.8 million in stockholders’ equity. Shares outstanding were 17,427,559 as of October 10, 2025. Management cites tariff uncertainty and de minimis changes as headwinds while scaling the pharma segment.
Lakeside Holding Limited reported changes to its Board of Directors. On September 30, 2025, the Board accepted the resignation of director Ms. Yiye Zhou, effective immediately, and stated that her departure was not due to any disagreement with the company’s operations, policies, or practices.
On the same date, the Board elected Mr. Aik Siang Goh, a technology-focused entrepreneur and executive with over two decades of experience, to serve as a director. Mr. Goh has held senior roles at companies including EdgeMatrix Computing, Chuang House Capital, Amazon Web Services, Fosun Group, Hewlett Packard Enterprise, Dell, and HP. The Board determined that he is an independent director, an “audit committee financial expert,” and a “Non-Employee Director” under applicable Nasdaq and SEC rules.
Mr. Goh will serve on the Audit Committee, the Compensation Committee, and as both a member and chair of the Nominating and Corporate Governance Committee. His compensation will match that of other non-employee directors, and the company reports no related party transactions with him requiring disclosure.
Lakeside Holding Limited has resolved a prior Nasdaq listing issue. The company previously received a notice on July 28, 2025 stating that its common stock had traded below the Nasdaq Capital Market’s minimum bid price of $1.00 per share for 30 consecutive business days, from June 12 to July 28, 2025, putting its listing at risk under Nasdaq Listing Rule 5550(a)(2).
On September 29, 2025, Lakeside received a letter from Nasdaq’s Listing Qualifications staff confirming that it has regained compliance with the minimum bid price requirement, and the matter is now closed. This means the company’s common stock, which trades on the Nasdaq Capital Market under the symbol LSH, currently remains in good standing with this specific listing standard.
Lakeside Holding Limited reported leadership and board changes. The board accepted Lan Su’s resignation as Chairman and Chief Operating Officer, effective immediately, while he continues as general manager of subsidiary Hupan Pharmaceutical (Hubei) Co., Ltd. The board elected Yang Li as a director and appointed him Chief Operating Officer and Chairman of the Board, bringing prior CEO, technology, and investment experience.
The board also elected Xiaoou Li as a new independent director to fill a vacancy. She has more than nine years of financial industry experience and has been designated an audit committee financial expert. She will serve on the audit, compensation, and nominating and corporate governance committees. Following these changes, the board has five members, with a majority independent under Nasdaq rules. The company states that Mr. Su’s resignation is not due to any disagreement and that there are no related-party transactions involving the new directors requiring disclosure.
Lakeside Holding Limited reported that board member Ms. Cynthia Vuong resigned from the Board of Directors effective August 15, 2025. She also stepped down from the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. The company stated that her resignation was not due to any disagreement with the company on its operations, policies, or practices, indicating this is described as a non-conflict departure.
Lakeside Holding Limited filed an amendment to its current report to correct the disclosed terms of a private placement. The amendment restates Item 1.01 and Item 9.01 to show that the aggregate number of shares issued was 2,000,000 (previously reported as 1,500,000) and that the purchase price per share was $0.75 (previously reported as $1.00). The amendment references an Amended Securities Purchase Agreement filed as Exhibit 10.1 (dated August 5, 2025).
Other than these corrections, the Original report filed on July 22, 2025 remains unchanged. The amendment is signed by CFO Long Yi on August 11, 2025. The filing identifies the company as a Nasdaq-listed registrant under the ticker LSH and indicates it is an emerging growth company.
Lakeside Holding Limited entered into a Securities Purchase Agreement to issue an aggregate of 1,807,229 shares of common stock at $0.83 per share, producing gross proceeds of approximately $1,500,000.07. The agreement contains customary representations, warranties and covenants, and the company intends to use the net proceeds for general corporate purposes.
The offering was completed as a private placement relying on exemptions under Section 4(a)(2) and/or Regulation S of the Securities Act; the shares are unregistered and may not be offered or sold in the United States absent registration or an applicable exemption. The form of the Securities Purchase Agreement is filed as Exhibit 10.1.